Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;4(1):59-72.
doi: 10.1177/2040620712464509.

Factor VIII inhibitors in hemophilia A: rationale and latest evidence

Char Witmer  1 , Guy Young
Affiliations

Factor VIII inhibitors in hemophilia A: rationale and latest evidence

Char Witmer et al. Ther Adv Hematol. 2013 Feb.

Abstract

Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII. Inhibitor development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and a decreased quality of life. The development of an inhibitor is the result of a complex interaction between a patient's immune system and genetic and environmental risk factors. The mainstay of treatment is the eradication of the inhibitor through immune tolerance. This review summarizes the current evidence regarding inhibitor risk factors, eradication, and hemostatic bypassing agents.

Keywords: FVIII; FVIII alloantibodies; hemophilia A; immune tolerance; inhibitors; risk factors.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: GY has received honoraria as a speaker for Baxter and Novo Nordisk. CW has no conflicts of interest to declare.

References

    1. Addiego J., Kasper C., Abildgaard C., Hilgartner M., Lusher J., Glader B., et al. (1993) Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 342: 462–464 - PubMed
    1. Aledort L., Dimichele D. (1998) Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 4: 68. - PubMed
    1. Astermark J. (2006) Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 12(Suppl. 3): 52–60 - PubMed
    1. Astermark J., Berntorp E., White G., Kroner B. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7: 267–272 - PubMed
    1. Astermark J., Donfield S., DiMichele D., Gringeri A., Gilbert S., Waters J., et al. (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109: 546–551 - PubMed

LinkOut - more resources